ABUS241220C1500
- 0.00
- 0.000.00%
Arbutus Biopharma Newsroom
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Chardan Capital Maintains Buy on Arbutus Biopharma, Raises Price Target to $5
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5
Arbutus Biopharma Analyst Ratings
Express News | Barinthus Biotherapeutics Shares Are Trading Lower. The Company Announced Data From the Ongoing Phase 2b HBV003 Clinical Trial
Arbutus Biopharma's Promising CHBV Treatment Results
Arbutus Biopharma's Trial Boosts Hepatitis B Treatment
Express News | Arbutus and Barinthus Bio Announce New Data From the IM-Prove II Trial Showing That the Addition of Nivolumab Increased Rates of Hbsag Loss in People With Chronic Hepatitis B
Arbutus to Present at Jefferies London Healthcare Conference
Arbutus Biopharma's Promise and Risks: A Hold Rating Amid Early Trial Success and Legal Uncertainty
H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
Q3 2024 Arbutus Biopharma Corp Earnings Call
Arbutus Biopharma Is Maintained at Buy by Chardan Capital
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $4.5
Arbutus Biopharma Price Target Raised to $4.50 From $4 at Chardan
Express News | Arbutus Biopharma Corp Files for Mixed Shelf of up to $300 Mln - SEC Filing
Arbutus Biopharma | 10-Q: Q3 2024 Earnings Report
Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript
JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5